Stem-cell transplantation in children and adults with sickle cell disease: an update

Area of Science:

• Hematology
• Transplantation Medicine
• Genetic Blood Disorders

Background:

• Sickle cell disease (SCD) causes significant health issues and reduces quality of life.
• Hydroxyurea can manage severe SCD, but hematopoietic stem-cell transplantation (HSCT) is the only curative treatment.
• HSCT shows high survival rates in children with SCD following myeloablative conditioning.

Purpose of the Study:

• To explore the potential of HSCT as a curative intervention for adults with severe sickle cell disease.
• To address the challenges and limitations of HSCT for SCD patients, particularly in adults.
• To evaluate the efficacy of reduced-intensity conditioning regimens in adult SCD patients.

Main Methods:

• Review of multicenter trials on HSCT outcomes in pediatric SCD patients.
• Analysis of the application and outcomes of reduced-intensity HSCT regimens in adult SCD patients.
• Identification of donor availability as a primary limitation for HSCT in SCD.

Main Results:

• Myeloablative HSCT in children with SCD demonstrates high overall survival (93-97%) and event-free survival (82-86%).
• Reduced-intensity HSCT regimens show promising results in adult SCD patients, though data is from a small cohort.
• The primary barrier to widespread HSCT for SCD remains the scarcity of matched HLA sibling donors.

Conclusions:

• HSCT is the only curative treatment for sickle cell disease.
• While effective in children, expanding HSCT to adults requires addressing risks associated with conditioning regimens.
• Increasing donor availability is crucial for making HSCT a more accessible curative option for all SCD patients.